Welcome to our dedicated page for NewGenIvf Group SEC filings (Ticker: NIVFW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NewGenIvf Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NewGenIvf Group's regulatory disclosures and financial reporting.
HRT Financial LP, a ten percent owner of NewGenIvf Group Ltd, reported open-market purchases of the company’s Common Stock. On May 22, 2026 and May 26, 2026, it bought a combined 165,534 shares at prices of $0.99 and $0.92 per share. Following these transactions, HRT Financial LP directly holds 139,878 shares of NewGenIvf Group Ltd common stock.
HRT Financial LP, a ten percent owner of NewGenIvf Group Ltd, reported open-market purchases of the company’s Common Stock. On May 22, 2026 and May 26, 2026, it bought a combined 165,534 shares at prices of $0.99 and $0.92 per share. Following these transactions, HRT Financial LP directly holds 139,878 shares of NewGenIvf Group Ltd common stock.
NewGenIvf Group Ltd disclosed that HRT FINANCIAL LP, identified as a ten percent owner, has reported its beneficial ownership on a Form 3. The filing shows HRT FINANCIAL LP holding 111,885 shares of NewGenIvf Group Ltd common stock directly, with no specific buy or sell transaction reported.
NewGenIvf Group Ltd disclosed that HRT FINANCIAL LP, identified as a ten percent owner, has reported its beneficial ownership on a Form 3. The filing shows HRT FINANCIAL LP holding 111,885 shares of NewGenIvf Group Ltd common stock directly, with no specific buy or sell transaction reported.
NewGenIVF Group Limited has entered into a strategic investment agreement with K25.ai, an APAC-focused, AI-powered live-streaming watch-to-predict platform. NewGenIVF plans an initial US$2 million investment at a US$100 million pre-money valuation, with an option to increase its total investment to up to US$10 million, all subject to definitive agreements and closing conditions.
The companies also plan an exclusive agency partnership under which NewGenIVF would promote and help develop K25.ai in permitted APAC markets, earning commissions based on gross profit from customers it introduces or services. K25.ai will nominate three independent non-executive director candidates for NewGenIVF’s board, which is expected to expand from five to eight directors following any appointments.
NewGenIVF Group Limited has entered into a strategic investment agreement with K25.ai, an APAC-focused, AI-powered live-streaming watch-to-predict platform. NewGenIVF plans an initial US$2 million investment at a US$100 million pre-money valuation, with an option to increase its total investment to up to US$10 million, all subject to definitive agreements and closing conditions.
The companies also plan an exclusive agency partnership under which NewGenIVF would promote and help develop K25.ai in permitted APAC markets, earning commissions based on gross profit from customers it introduces or services. K25.ai will nominate three independent non-executive director candidates for NewGenIVF’s board, which is expected to expand from five to eight directors following any appointments.
NewGenIvf Group Ltd Chairman & CEO Siu Wing Fung Alfred received a grant of stock options to acquire 56,851 Class B Ordinary Shares at an exercise price of US$0.0001 per share under the company’s 2024 Share Incentive Plan.
The options vest monthly from 4 June 2026 through 4 May 2029, starting with 5,685 options and then 1,462 options on most monthly vesting dates, with 1,458 options vesting in the final tranche. The options expire on 4 May 2033, and following this grant he holds 56,881 stock options directly.
NewGenIvf Group Ltd Chairman & CEO Siu Wing Fung Alfred received a grant of stock options to acquire 56,851 Class B Ordinary Shares at an exercise price of US$0.0001 per share under the company’s 2024 Share Incentive Plan.
The options vest monthly from 4 June 2026 through 4 May 2029, starting with 5,685 options and then 1,462 options on most monthly vesting dates, with 1,458 options vesting in the final tranche. The options expire on 4 May 2033, and following this grant he holds 56,881 stock options directly.
NewGenIvf Group Ltd reported that Chief Marketing Officer Fong Hei Yue Tina received a grant of stock options to acquire 56,851 Class B Ordinary Shares. The options carry an exercise price of US$0.0001 per share and were granted under the company’s 2024 Share Incentive Plan.
The award vests over time: 5,685 options on June 4, 2026, 1,462 options on the 4th day of each month from July 4, 2026 through April 4, 2029, and 1,458 options on May 4, 2029. The options expire on May 4, 2033, and following this grant she holds 56,890 options directly.
NewGenIvf Group Ltd reported that Chief Marketing Officer Fong Hei Yue Tina received a grant of stock options to acquire 56,851 Class B Ordinary Shares. The options carry an exercise price of US$0.0001 per share and were granted under the company’s 2024 Share Incentive Plan.
The award vests over time: 5,685 options on June 4, 2026, 1,462 options on the 4th day of each month from July 4, 2026 through April 4, 2029, and 1,458 options on May 4, 2029. The options expire on May 4, 2033, and following this grant she holds 56,890 options directly.
NewGenIvf Group Limited files its annual report highlighting severe liquidity pressure, heavy dilution risk and a high‑risk diversification strategy beyond fertility services. As of December 31, 2025, cash and cash equivalents were about US$758,621, while US$5,266,000 of convertible promissory notes remained outstanding as of March 30, 2026, raising going concern uncertainty.
The company can draw up to US$100,000,000 under an equity line with White Lion, of which roughly US$15.55 million has already converted to equity, alongside 1,224,328 warrants and 113,703 share-incentive shares that may further dilute holders. NewGenIvf is pivoting from fertility into Solana staking, digital-asset tokenization and UAE real estate, including a planned investment of up to US$30 million in SOL and a novel term sheet to receive up to 600,000 SOL for shares. The firm also details recent Nasdaq listing deficiencies and reliance on repeated reverse stock splits to maintain listing.
NewGenIvf Group Limited files its annual report highlighting severe liquidity pressure, heavy dilution risk and a high‑risk diversification strategy beyond fertility services. As of December 31, 2025, cash and cash equivalents were about US$758,621, while US$5,266,000 of convertible promissory notes remained outstanding as of March 30, 2026, raising going concern uncertainty.
The company can draw up to US$100,000,000 under an equity line with White Lion, of which roughly US$15.55 million has already converted to equity, alongside 1,224,328 warrants and 113,703 share-incentive shares that may further dilute holders. NewGenIvf is pivoting from fertility into Solana staking, digital-asset tokenization and UAE real estate, including a planned investment of up to US$30 million in SOL and a novel term sheet to receive up to 600,000 SOL for shares. The firm also details recent Nasdaq listing deficiencies and reliance on repeated reverse stock splits to maintain listing.
NewGenIvf Group Ltd director and executive Alfred Siu Wing Fung, who serves as Chairman & CEO, has filed an initial Form 3 reporting his beneficial ownership in the company. The filing shows he holds 30 Class B Ordinary Shares, reported as direct ownership, with no buy or sell transactions disclosed.
NewGenIvf Group Ltd director and executive Alfred Siu Wing Fung, who serves as Chairman & CEO, has filed an initial Form 3 reporting his beneficial ownership in the company. The filing shows he holds 30 Class B Ordinary Shares, reported as direct ownership, with no buy or sell transactions disclosed.
NewGenIvf Group Ltd director Au Hok Man Jefferson has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. This filing establishes his status as a director at NewGenIvf, and the accompanying data show no insider buy, sell, or derivative transactions reported in this Form 3.
NewGenIvf Group Ltd director Au Hok Man Jefferson has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. This filing establishes his status as a director at NewGenIvf, and the accompanying data show no insider buy, sell, or derivative transactions reported in this Form 3.
NewGenIvf Group Ltd Chief Financial Officer Chan Chung Ho has filed an initial insider ownership report on Form 3 for the company’s ordinary shares. The filing lists him as an officer with the title Chief Financial Officer and does not report any insider transactions in the available data.
NewGenIvf Group Ltd Chief Financial Officer Chan Chung Ho has filed an initial insider ownership report on Form 3 for the company’s ordinary shares. The filing lists him as an officer with the title Chief Financial Officer and does not report any insider transactions in the available data.